Precision Medicine Online

AI Tools Stumped By HER2-Low Breast Cancer Just Like Pathologists, Study Finds

A study evaluated agreement between 10 AI digital pathology tools in assessing IHC-based HER2 expression and found the most variability in identifying HER2-low samples.
ascopubs.org

Estrogen Receptor Status by Immunohistochemistry Is Superior to the Ligand-Binding Assay for Predicting Response to Adjuvant Endocrine Therapy in Breast Cancer

Immunohistochemistry (IHC) is a newer technique for assessing the estrogen receptor (ER) status of breast cancers, with the potential to overcome many of the shortcomings associated with the ...
ascopubs.org

Clinical and Molecular Characteristics of High-Risk, Recurrent, or Metastatic Endometrial Cancer That Is Human Epidermal Growth Factor Receptor 2–Low

HER2 status was determined by immunohistochemistry (IHC) and dual in situ hybridization (DISH) on four studies of previously classified high-risk EC (PORTEC-3 and Medical Spectrum Twente cohort), ...
MedPage Today

HER2 Low and Ultralow Designations Open Door to Expansion of ADCs in Breast Cancer

The HER2-low and HER2-ultralow breast cancer subtype designations have led to a changed landscape in HER2-directed therapies, as well as a desire for more sensitive assays that may better quantify ...
The Scientist

Leica Biosystems Launches ChromoPlex III Detection System to Streamline Chromogenic Multiplex IHC for Reproducible, Digital-Ready Staining

Leica Biosystems, a global leader in anatomic and digital pathology solutions, today unveiled ChromoPlex III Triple Detection RUO, a chromogenic multiplex immunohistochemistry detection system ...